Everything below concerns Prohibited substance. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
Between the 3rd and 1st centuries BC, the Roman Republic established hegemony over the eastern Mediterranean, while its government developed into the one-person rule of an emperor. The Roman Empire enjoyed a period of relative stability until the 3rd century AD, when external threats and internal crises caused it to splinter, as regional armies acclaimed their generals as "soldier-emperors". One of these, Diocletian (r. 284–305), recognised that the state was too big to be ruled by a single person. He instituted the Tetrarchy, a system which divided the empire into eastern and western halves. The Tetrarchy quickly failed, but the division of the empire proved an enduring concept. Constantine I (r. 306–337) secured absolute power in 324. Over the next six years, he rebuilt the city of Byzantium as a new capital that he called "New Rome" (later named Constantinople). The old capital Rome was farther from the prosperous eastern provinces and in a less strategically important location; its esteem had already been somewhat lessened in the eyes of the "soldier-emperors", who ruled from the frontiers, and of the empire's population. Having been granted citizenship, the empire's subjects considered themselves just as Roman as those in the city of Rome. Constantine continued reforms of the empire's military and civil administration and instituted the gold solidus as a stable currency. He favoured Christianity and became an opponent of paganism.
=== 2010s === Stanton was elected into the Essendon leadership group for the 2010 season. Stanton amassed 477 possessions and kicked 13 goals in 20 games for an Essendon team which won seven matches and lost fifteen in a year that would see their coach, Matthew Knights, sacked one day after the conclusion of the regular season. Stanton polled six votes in the Brownlow Medal and finished fifth in the 2010 Crichton Medal with 167 votes. Stanton continued to improve during the year. Stanton led the club in kicks and handballs received and was in the top five for marks, handballs, inside-50s, rebound-50s and loose-ball gets. Into his ninth AFL season and in the Essendon leadership group, Stanton finished second in the 2011 Crichton Medal behind David Zaharakis. He played his 150th AFL game against Melbourne in Round 11. Wearing the number 5, his running and ability to accumulate possessions contributed to every victory during the 2012 season. He has now polled a career high 14 votes in the 2012 Brownlow Medal. In Round 6 of the 2012 AFL season, Stanton collected a record 193 Dream Team points in Essendon's win against the Brisbane Lions at Docklands Stadium. His statistics included: 39 disposals (from 32 kicks and 7 handballs), 17 marks and 8 tackles. As of 2015, it remains the highest Dream Team score by a midfielder. Stanton played his 200th game in Round 20, 2013 against West Coast at Etihad Stadium.
==== Elimination ==== Only 1% of the drug was eliminated in urine unchanged, whereas 13% was eliminated as O-H-LSD within 24 hours. Aghajanian and Bing (1964) found LSD had an elimination half-life of only 175 minutes (about 3 hours); however, using more accurate techniques, Papac and Foltz (1990) reported that 1 μg/kg oral LSD given to a single male volunteer had an apparent plasma half-life of 5.1 hours, with a peak plasma concentration of 5 ng/mL at 3 hours post-dose. In a more modern 2015 study, concentrations of LSD decreased following first-order kinetics with a half-life of 3.6 ± 0.9 hours and a terminal half-life of 8.9 ± 5.9 hours. A 2026 review found half-lives ranging from 3.0 to 4.3 hours in different studies. LSD has a longer half-life of on average 8 hours in CYP2D6 poor metabolizers or people taking CYP2D6 inhibitors due to slower metabolism.
Sources: en.wikipedia.org
Activation: Recruitment of osteoclasts to specific bone sites Resorption: Osteoclastic removal of old bone Reversal: Transition from resorption to formation Formation: Osteoblastic deposition of new osteoid Mineralization: Transformation of osteoid into mineralized bone Throughout this process, osteoblasts produce the unmineralized organic matrix that subsequently undergoes calcification to form new bone tissue.
== History == The history of today's Gelita AG in Eberbach dates back to 1875, when the production of gelatin was started in Schweinfurt. Gelita was preceded by the founding of the "Gebrüder Köpff Company", Heinrich Koepff's small tannery, in 1883. Shaken by the economic crisis of the time, Heinrich saw a way out of his misery in gelatin production. The raw material for this could be purchased cheaply, as it was produced in the large tanneries as residual material. With around 60 employees, the factory was already producing photographic gelatin in 1884, which was an important material for the rapidly emerging photography in the 19th century. In 1887, the Koepff brothers acquired the competing company A. & C. Wolff in Heilbronn. Both locations had 320 employees who produced 400 tonnes of gelatin per year. In 1901, a major fire destroyed large parts of the factory. The brothers quarreled over reconstruction. Heinrich went to Heilbronn and Paul Koepff continued to run the rebuilt plant alone under the name Göppinger Gelatin Factory Paul Koepff. In 1911, he sold the factory to DGF AG, which already operated gelatin factories in Schweinfurt and Höchst. Paul Koepff was henceforth on the board of directors and continued to manage his former company as director. In 1929, Paul Koepff jr. took over the management of the Göppingen plant from his father, who died in 1953. The Gelita Brand was introduced in 1934. In 1937, the DGF was accused of violating foreign trade regulations and leading employees were arrested.
== Plot == Prior to the Combine invasion, Ravenholm was a small mining town in Eastern Europe. The town served as an outpost for the Resistance against the Combine occupation. The Combine eventually bombarded the town with artillery shells containing headcrabs, alien parasites which attack organisms and turn them into zombies. Ravenholm's entire population was zombified, which led the Resistance to abandon the town. Shortly before the level, companion Alyx Vance states to protagonist Gordon Freeman, whom the player controls, that "we don't go [to Ravenholm] anymore", foreshadowing its overrun nature. The Resistance base, Black Mesa East, is attacked by Combine forces after the player obtains the Gravity Gun. Alyx's pet robot Dog opens a door to a tunnel leading to Ravenholm, directing the player to the town's outskirts. When the player first enters the ghost town in "We Don't Go To Ravenholm...", the soundtrack shifts to a traditional horror score, and the level contains a pair of disembodied legs hanging from a tree before discovering the town is infested with headcrabs and zombies. New enemies are introduced in the level, including poison headcrabs that can set the player's health to one point before it gradually regenerates. Fast zombies and headcrabs are quicker than their counterparts. Fast zombies can climb drainage pipes. Poisonous zombies are slow but have large amounts of health and carry poison headcrabs on their back that they can throw at the player.
Sources: en.wikipedia.org
Clinical trials involving new drugs are commonly classified into five phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug development process will normally proceed through phases I–IV over many years, frequently involving a decade or longer. If the drug successfully passes through phases I, II, and III, it will usually be approved by the national regulatory authority for use in the general population. Phase IV trials are performed after the newly approved drug, diagnostic or device is marketed, providing assessment about risks, benefits, or best uses.
β-Endorphin release in response to exercise has been known and studied since at least the 1980s. Studies have demonstrated that serum concentrations of endogenous opioids, in particular β-endorphin and β-lipotropin, increase in response to both acute exercise and training. The release of β-endorphin during exercise is associated with a phenomenon colloquially known in popular culture as a runner's high. Acute aerobic exercise significantly increases circulating β-endorphin concentrations, with elevations closely correlated to exercise intensity and the onset of the 'runner’s high'.
== History == 2,3-Dihydro-LSD was first described in the scientific literature by Charles Gorodetzky and Harris Isbell at the Addiction Research Center of the National Institute of Mental Health (subsequently part of the National Institute on Drug Abuse) by 1964. However, it had first been synthesized and studied in animals by Botand Berde and Rudolph Bircher at Sandoz Pharmaceuticals, but their findings were unpublished. Sandoz Pharmaceuticals supplied the 2,3-dihydro-LSD used by Gorodetzky and Isbell in their clinical study.
=== Beyond the tongue === The gut has its own umami taste receptors. The ATP taste signals are conveyed to the brain, probably through afferent branches of the vagus nerve or the afferent sensory nerves in the mouth. The brain uses this information to regulate behaviors and preferences in mice. This is an example of the gut–brain axis.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.